



Nova Leap Health Corp.

**Unaudited Condensed Interim Consolidated Financial Statements
For the three and nine months ended September 30, 2025 and 2024**

(United States dollars)

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Financial Position

(United States dollars)

As at	September 30, 2025 \$	December 31, 2024 \$
ASSETS		
Current assets		
Cash and cash equivalents	1,571,716	1,402,767
Accounts receivable	1,970,794	1,697,910
Prepaid expenses	277,261	319,057
Total current assets	3,819,771	3,419,734
Non-current assets		
Property and equipment	789,586	976,560
Intangible assets	654,655	634,209
Goodwill	17,008,199	15,972,551
Deferred income tax asset	1,314,672	1,385,246
Total non-current assets	19,767,112	18,968,566
TOTAL ASSETS	23,586,883	22,388,300
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	1,781,807	1,563,605
Client deposits payable	41,922	49,804
Demand loans (note 4)	1,879,305	1,211,204
Promissory notes (note 5)	119,680	111,621
Lease liability	271,698	299,683
Total current liabilities	4,094,412	3,235,917
Non-current liabilities		
Promissory notes (note 5)	209,492	218,575
Lease liability	530,595	684,872
Total non-current liabilities	740,087	903,447
TOTAL LIABILITIES	4,834,499	4,139,364
SHAREHOLDERS' EQUITY		
Share capital (note 6)	19,104,212	19,104,212
Contributed surplus	2,363,878	2,309,419
Accumulated other comprehensive loss	(1,710,575)	(2,295,700)
Deficit	(1,005,131)	(868,995)
TOTAL SHAREHOLDERS' EQUITY	18,752,384	18,248,936
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	23,586,883	22,388,300

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Approved on behalf of the Board of Directors

“Michael O’Keefe”

(signed)

Director

“Chris Dobbin”

(signed)

Director

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income

(United States dollars)

For the	Three months ended September 2025 \$	2024 \$	Nine months ended September 2025 \$	2024 \$
Revenues				
Service revenues	8,264,326	6,406,528	23,379,022	19,174,781
Operating expenses				
Cost of services	4,991,636	3,972,646	14,115,730	11,862,223
	3,272,690	2,433,882	9,263,292	7,312,558
Corporate and administrative expenses				
Head office and operations management	1,905,226	1,506,263	5,661,590	4,586,876
General & administrative	696,758	548,503	2,064,029	1,576,868
Amortization and depreciation	233,427	146,169	639,070	435,337
Stock-based compensation	18,726	24,837	54,459	70,949
	2,854,137	2,225,772	8,419,148	6,670,030
Income from operating activities	418,553	208,110	844,144	642,528
Other expenses				
Foreign exchange gain (loss)	295,214	(214,905)	(521,239)	310,395
Forgiveness of government loans	-	-	-	29,544
Finance expense	(83,750)	(18,419)	(271,484)	(61,614)
Acquisition related expenses	(43,145)	(116,247)	(119,566)	(171,001)
Other expenses	-	(6,497)	-	(18,898)
	168,319	(356,068)	(912,289)	88,426
Income (loss) before income taxes	586,872	(147,958)	(68,145)	730,954
Income taxes				
Deferred income tax expense (recovery)	116,536	50,038	(14,233)	209,129
Current income tax expense (recovery)	44,165	9,875	82,224	29,625
	160,701	59,913	67,991	238,754
Net income (loss)	426,171	(207,871)	(136,136)	492,200
Items that will be reclassified subsequently to profit or loss				
Foreign exchange (loss) gain on translation to presentation currency	(357,051)	249,273	585,125	(367,434)
Total comprehensive income	69,120	41,402	448,989	124,766
Net income (loss) per share – basic and diluted (note 7)	\$0.005	(\$0.002)	(\$0.002)	\$0.006

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(United States dollars)

	Common shares	Share capital \$	Contributed surplus \$	Accumulated other comprehensive income (loss) \$	Deficit \$	Total shareholders' equity \$
Balance at January 1, 2025	87,314,252	19,104,212	2,309,419	(2,295,700)	(868,995)	18,248,936
Stock-based compensation	-	-	54,459	-	-	54,459
Net loss for the period	-	-	-	-	(136,136)	(136,136)
Gain on foreign currency translation	-	-	-	585,125	-	585,125
Balance at September 30, 2025	87,314,252	19,104,212	2,363,878	(1,710,575)	(1,005,131)	18,752,384
Balance at January 1, 2024	86,209,252	18,959,250	2,263,219	(778,235)	(2,247,463)	18,196,771
Stock-based compensation	-	-	70,949	-	-	70,949
Net income for the period	-	-	-	-	492,200	492,200
Other comprehensive loss for the period	-	-	-	(367,434)	-	(367,434)
Balance at September 30, 2024	86,209,252	18,959,250	2,334,168	(1,145,669)	(1,755,263)	18,392,486

The accompanying notes form an integral part of these unaudited condensed interim consolidated financial statements.

Nova Leap Health Corp.

Unaudited Condensed Interim Consolidated Statements of Cash Flows

(United States dollars)

For the	Three months ended September 30		Nine months ended September 30	
	2025	2024	2025	2024
	\$	\$	\$	\$
Cash provided by (used in)				
Operating activities				
Net income (loss) for the period	426,171	(207,871)	(136,136)	492,200
Adjustments for items not affecting cash:				
Amortization and depreciation	233,427	146,169	639,070	435,337
Deferred income tax expense (recovery)	116,536	50,038	(14,233)	209,129
Stock-based compensation	18,726	24,837	54,459	70,949
Finance expense	79,608	19,414	254,837	58,683
Unrealized foreign exchange (gain) loss	(298,110)	218,271	502,351	(318,116)
Forgiveness of government loans	-	-	-	(29,544)
Net change in non-cash operating working capital (note 8)	(105,468)	36,401	(20,768)	130,634
Cash provided by operating activities	470,890	287,259	1,279,580	1,049,272
Investing activities				
Acquisition of businesses (note 3)	-	-	(1,242,934)	(250,000)
Cash used in investing activities	-	-	(1,242,934)	(250,000)
Financing activities				
Proceeds from demand loan, net of debt issue costs (note 4)	-	-	937,811	-
Repayment of demand loans and transaction costs (note 4)	(123,294)	-	(352,699)	-
Repayment of government loans	-	-	-	(59,333)
Interest payments on demand loans (note 4)	(41,783)	-	(128,365)	-
Repayment of promissory notes and interest (note 5)	-	-	(27,500)	-
Repayment of lease liability and interest	(119,926)	(91,772)	(312,131)	(270,671)
Cash (used in) provided by financing activities	(285,003)	(91,772)	117,116	(330,004)
Effect of foreign exchange rate change on cash and cash equivalents	(7,455)	145	15,187	(3,033)
Increase in cash and cash equivalents for the period	178,432	195,632	168,949	466,235
Cash and cash equivalents - beginning of period	1,393,284	1,165,368	1,402,767	894,765
Cash and cash equivalents - end of period	1,571,716	1,361,000	1,571,716	1,361,000

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

1. Nature of operations

Nova Leap Health Corp. (the “Corporation”) is the parent company and was incorporated under the Canada Business Corporations Act on November 16, 2015. The principal activities of the Corporation and its subsidiaries (the “Group”) is to provide home and home health care services to clients. The Group is currently providing services in the United States in nine states as well as in Nova Scotia, Canada. The Corporation is a public corporation whose shares are listed and posted for trading on the TSX Venture Exchange under the symbol NLH and the over-the-counter market (OTCQX) in the United States under the symbol NVLPF.

These Unaudited Condensed Interim Consolidated Financial Statements include the accounts of the Corporation and its United States (“US”) and Canadian subsidiaries and are presented in United States dollars (“USD”) which is the functional currency of the majority of the Group’s business operations. The registered head office of the Corporation is located at 7071 Bayers Road, Suite 3006, Halifax, NS Canada B3L 2C2.

The Unaudited Condensed Interim Consolidated Financial Statements were approved by the Board of Directors on November 6, 2025.

2. Material accounting policies

Statement of compliance

These Unaudited Condensed Interim Consolidated Financial Statements are prepared in accordance with IAS 34, *Interim Financial Reporting* as issued by the International Accounting Standards Board (“IASB”). These Unaudited Condensed Interim Consolidated Financial Statements were prepared using the same accounting policies and methods of computation and are subject to the same use of estimates and judgments as the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2024. These Unaudited Condensed Interim Consolidated Financial Statements do not include all disclosures required by IFRS Accounting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”) for annual consolidated financial statements and accordingly should be read in conjunction with the Corporation’s Audited Consolidated Financial Statements for the year ended December 31, 2024, prepared in accordance with IFRS Accounting Standards.

3. Business acquisitions

On January 20, 2025, the Corporation acquired 100% of the shares of two related home care businesses in Nova Scotia, Canada. On May 5, 2025, the Corporation acquired the assets of a home care business located in Nova Scotia, Canada. The Corporation determined that both acquisitions met the definition of a business in accordance with IFRS 3 Business Combinations (“IFRS 3”).

The acquisition on January 20, 2025 was a non-arm’s length transaction pursuant to TSX Venture Exchange policies as the businesses were previously controlled by the Chief Executive Officer and a shareholder holding more than 10% of the outstanding shares of the Corporation. The acquisition was approved by disinterested shareholders of the Corporation at a meeting of shareholders held on January 8, 2025.

Details of the acquisitions, including the preliminary allocations of purchase price, are as follows:

Acquisition date	Nova Scotia	Nova Scotia
	May 5, 2025	January 20, 2025
	\$	\$
Total purchase price	279,919	1,005,725
Fair value of consideration transferred		
Cash	279,919	963,015
Working capital adjustment	-	42,710
Total	279,919	1,005,725

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

3. Business acquisitions (continued)

Recognized amounts of identifiable net assets

Working capital	-	42,710
Property and equipment	-	52,995
Intangible assets - customer lists	78,949	125,611
Intangible assets - non-compete agreements	28,708	125,611
Lease liability	-	(39,161)
Deferred income tax liability	-	(72,854)
Goodwill	172,262	770,813
Total	279,919	1,005,725

Acquisition costs	22,984	70,662
--------------------------	--------	--------

Contribution to Group Results

Revenue from date of acquisition to reporting date	444,941	1,498,556
Income from operating activities from date of acquisition to reporting date	41,388	92,370

Goodwill

Goodwill is primarily related to growth expectations, expected future profitability and the assembled workforce.

Proforma Group Results and Other

Proforma Group results based on acquiring the assets of all closed acquisitions at January 1, 2025

If the shares or assets of the businesses acquired during the period had been acquired on January 1, 2025, revenue of the Group for the nine months ended September 30, 2025 would have increased by approximately \$480,000 and income from operating activities would have increased by approximately \$45,000.

Business acquisitions completed in 2024

During 2024, the Corporation completed two business acquisitions. The combined total purchase price was \$1,892,783 and resulted in intangible assets of \$360,000 and goodwill of \$1,532,783.

4. Demand loans

The changes in the demand loans for the period are as follows:

	September 30, 2025	December 31, 2024
	\$	\$
At amortized cost:		
Balance, beginning of period	1,211,204	-
Proceeds from issuance of demand loan	963,015	1,316,000
Debt issue costs	(25,204)	(85,599)
Guarantee insurance costs	(23,265)	(5,760)
Effective interest	183,628	15,034
Interest payments	(128,365)	(6,538)
Principal repayment in cash	(329,434)	(21,933)
Foreign exchange loss	27,726	-
Balance, end of period	1,879,305	1,211,204
Fair value	1,955,801	1,294,067

During the year ended December 31, 2024, the Corporation entered into an agreement to amend its existing credit agreement with its primary lender. The amended credit facilities provided the Corporation with access to non-revolving demand loans

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

4. Demand loans (continued)

of CAD\$1,380,000 and USD\$6,007,000 to assist with financing business acquisitions. As at December 31, 2024, USD\$1,316,000 was used to finance the business acquisition completed on December 14, 2024.

During the nine months ended September 30, 2025, the Corporation received proceeds of CAD\$1,380,000 from the issuance of a demand loan to finance the business acquisition completed on January 20, 2025. The loan is repayable over a maximum amortization period of 60 months and interest is payable at the CAD prime rate plus 1.5%.

The non-revolving loans outstanding are repayable on demand, provided that until demands are made, blended monthly payments comprising the principal and interest be paid, based on the US base rate plus 1.5% and the CAD prime rate plus 1.5%, over the maximum amortization period. The US base rate at September 30, 2025 was 7.75% and the CAD prime rate at September 30, 2025 was 4.70%.

The Corporation also has access to a \$1,077,509 (CAD\$1,500,000) revolving operating facility for working capital purposes from a Schedule 1 Canadian bank. The interest rate is the CAD prime rate plus 1.5%. Interest is calculated monthly in arrears, and payable on the last day of each month. The facility is repayable on demand. There was no outstanding balance on this facility as at September 30, 2025 or December 31, 2024.

The revolving operating facility and demand loans are secured through a registered General Security Agreement and joint and several unlimited guarantees from the Corporation's US and Canadian subsidiaries.

5. Promissory notes

The changes in the promissory notes for the period are as follows:

	September 30, 2025	December 31, 2024
	\$	\$
Balance, beginning of period	330,196	117,509
Issuance of promissory notes for acquisition of business (note 3)	-	326,783
Effective interest	26,476	11,904
Repayments	(27,500)	(126,000)
Balance, end of period	329,172	330,196
Current portion	119,680	111,621
Non-current portion	209,492	218,575
Balance, end of period	329,172	330,196
Fair value	331,977	333,067

The promissory notes were all initially recorded at fair value using market interest rate of 9.75-10.5% and subsequently measured at amortized cost using the effective interest rate method.

The promissory notes are subject to a Guaranty Agreement from the Corporation and are subordinated to the demand loans (note 4).

6. Share capital

a. Authorized:

Unlimited number of common shares, without nominal or par value.

b. Issued and outstanding:

	September 30, 2025		December 31, 2024	
	Number of Shares	Cost \$	Number of Shares	Cost \$
Balance, beginning and end of period	87,314,252	19,104,212	86,209,252	18,959,250
Stock options exercised	-	-	1,105,000	144,962
	87,314,252	19,104,212	87,314,252	19,104,212

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

7. Earnings per share

Basic earnings per share is calculated based on the weighted average number of shares outstanding during the period. Diluted earnings per share assumes that stock options and DSUs have been exercised on the later of the beginning of the period and the date granted. For the three months ended September 30, 2025, 6,325,000 stock options were excluded from the computation of diluted earnings per share because their effect would have been anti-dilutive. For the nine months ended September 30, 2025, all stock options and DSUs were excluded from the computation of diluted earnings per share because their effect would have been anti-dilutive.

For the three and nine months ended September 30, 2024, all and 5,325,000 stock options and DSUs respectively were excluded from the computation of diluted income per share because their effect would have been anti-dilutive.

The following table summarizes the basic and diluted weighted average number of shares:

	Three months ended September 30		Nine months ended September 30	
	2025	2024	2025	2024
Weighted average number of shares used in basic earnings per share	87,314,252	86,209,252	87,314,252	86,209,252
Shares deemed to be issued for no consideration in respect of share-based payments	639,024	1,264,569	566,081	1,227,133
Weighted average number of shares used in basic and diluted earnings per share	87,953,276	87,473,821	87,880,333	87,436,385

8. Supplemental cash flow information

The change in the non-cash operating working capital is as follows:

	Three months ended September 30		Nine months ended September 30	
	2025	2024	2025	2024
	\$	\$	\$	\$
Accounts receivable	(320,471)	(159,324)	(272,884)	(28,077)
Prepaid expenses	49,247	130,996	41,796	(3,332)
Accounts payable and accrued liabilities	169,355	67,930	218,202	176,529
Client deposits payable	(3,599)	(3,201)	(7,882)	(14,486)
	(105,468)	36,401	(20,768)	130,634
Supplemental information:				
Interest paid	62,276	15,792	180,159	49,667
Income taxes paid	32,897	-	93,128	40,834

9. Related party transactions

Transactions with related parties are in the normal course of operations and are measured at the exchange amount, which is the amount agreed to by the parties. Related parties include members of the Board of Directors, as well as the Chief Executive Officer and the Chief Financial Officer.

Corporate and administrative expenses include the following related party remuneration expenses:

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

9. Related party transactions (continued)

	Three months ended September 30		Nine months ended September 30	
	2025	2024	2025	2024
	\$	\$	\$	\$
Management compensation	109,071	110,182	339,718	338,791
Directors' compensation	34,845	35,200	102,964	105,864
Stock-based compensation	16,050	20,925	46,001	65,287
	159,966	166,307	488,683	509,942

As at September 30, 2025, there was \$49,027 included in accounts payable and accrued liabilities for amounts owed to officers of the Corporation for compensation and expense reimbursements (December 31, 2024 – \$63,574) and \$10,775 for amounts due to directors for directors' fees (December 31, 2024 – \$10,425).

On January 20, 2025, the Corporation acquired 100% of the shares of two affiliated Nova Scotia based home care businesses. The acquisition was a non-arm's length transaction as the shares were previously controlled by the Chief Executive Officer and a shareholder holding more than 10% of the outstanding shares of the Corporation (see note 3).

10. Financial instruments

The Group's risk management is coordinated at its Head Office, in close cooperation with the Board of Directors, and focuses on actively securing the Group's short to medium-term cash flows by maximizing cash flow from operations. The Group is exposed to various risks in relation to financial instruments. The main types of risks are credit risk, liquidity risk and market risk. The Group is exposed to the same risks in the current year as it was exposed to in the prior year. The most significant financial risks to which the Group is exposed are described below.

Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is exposed to this risk for various financial instruments, for example by granting receivables to customers and placing deposits.

The Group's maximum exposure to credit risk is limited to the carrying amount of financial assets recognized at the end of the reporting period, as summarized below:

Classes of financial assets – carrying amounts	September 30, 2025	December 31, 2024
	\$	\$
Cash and cash equivalents	1,571,716	1,402,767
Accounts receivable	1,970,794	1,697,910
	3,542,510	3,100,677

Credit risk management

The credit risk is managed on a group basis based on the Group's credit risk management policies and procedures. The credit risk in respect of cash balances held with banks is managed by only using major reputable financial institutions.

The Group does not specifically assess the credit quality of clients based on a credit rating but through an informal process while onboarding for service. Invoice terms are generally payable within thirty days. The ongoing credit risk is managed through regular review of the aging analysis.

At certain locations, clients are required to pay an upfront deposit, mitigating the credit risk. As at September 30, 2025, the Group had \$41,922 collected for client deposits (December 31, 2024 - \$49,804), representing approximately 2.1% of outstanding accounts receivable, billed and accrued (December 31, 2024 – 2.9%).

Liquidity risk

Liquidity risk is the risk that the Group might be unable to meet its obligations. The Group manages its liquidity needs by monitoring scheduled debt servicing payments for long-term financial liabilities as well as forecasting cash inflows and outflows due in day-to-day business. The data used for analysing these cash flows is consistent with that used in the contractual maturity analysis below.

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

10. Financial instruments (continued)

Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well as on the basis of a rolling 30-day projection. Long-term liquidity needs for a quarterly lookout period are identified monthly. Net cash requirements are compared to available cash balances and available borrowing facilities in order to determine headroom or shortfalls. This analysis shows that available borrowing facilities and available cash are expected to be sufficient for the next twelve months.

The Group considers expected cash flows from financial assets in assessing and managing liquidity risk, in particular its cash resources and accounts receivable. The Group's existing cash resources and accounts receivable, in addition to the current unused balance of the revolving operating facility and cash flow projections, are expected to be sufficient to meet current contractual cash outflow requirements. Cash flows from accounts and other receivables are all contractually due within 30 days.

The Group's financial liabilities have contractual maturities (including interest payments where applicable) as summarized below:

As at September 30, 2025	< 1 year \$	1-2 years \$	3-5 years \$	> 5 years \$
Accounts payable and accrued liabilities	1,781,807	-	-	-
Client deposits	41,922	-	-	-
Promissory notes, principal and interest	142,517	113,067	109,866	-
Demand loans, principal and interest	598,858	562,382	1,126,671	-
Lease liability, principal and interest	311,075	220,045	262,883	97,874
Total	2,876,179	895,494	1,499,420	97,874

As at December 31, 2024	< 1 year \$	1-2 years \$	3-5 years \$	> 5 years \$
Accounts payable and accrued liabilities	1,563,605	-	-	-
Client deposits	49,804	-	-	-
Promissory notes, principal and interest	143,767	139,317	109,866	-
Demand loans, principal and interest	397,790	367,428	895,268	-
Lease liability, principal and interest	354,501	274,957	329,262	147,955
Total	2,509,467	781,702	1,334,396	147,955

Market risk

The Group is exposed to market risk through its use of financial instruments and specifically to currency risk and interest rate risk, which result from both its operating and financing activities.

Foreign currency sensitivity

The Group's operations are predominantly carried out in United States dollars (USD). Exposure to currency exchange rates arise from the fact that the Group's equity offerings have been denominated in Canadian dollars (CAD) and will be denominated in CAD for the foreseeable future as the Corporation's shares are listed on a Canadian stock exchange and the Group has operations in Canada that transact in Canadian dollars

The Group's exposure to the Canadian dollar ("CAD") currency risk was as follows:

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

10. Financial instruments (continued)

	September 30, 2025	December 31, 2024
	CAD\$	CAD\$
Cash and cash equivalents	303,701	702,022
Accounts receivable	859,552	312,147
Accounts payable & accrued liabilities	(713,421)	(632,736)
Lease liability	(725,844)	(796,046)
Demand loans	(1,172,622)	-
	(1,448,634)	(414,613)

A change of 5.0% in the Canadian dollar exchange rate at September 30, 2025 would affect net income (loss) and deficit by approximately \$50,000 (September 30, 2024 - \$26,000).

Interest rate sensitivity

As at September 30, 2025, the Group is exposed to changes in market interest rates through bank borrowings at variable interest rates. An increase or decrease of 1% in interest rates would affect net income and comprehensive income and deficit by approximately \$17,000 on an annual basis (September 30, 2024 - \$nil).

Fair value

All financial assets and liabilities except for the demand loans and promissory notes are short-term. The carrying values of short-term financial assets and liabilities are a reasonable approximation of fair value. The fair value of the demand loans and promissory notes are disclosed in notes 4 and 5.

11. Segment reporting

Management identifies the Group's reportable segments as Canadian operations and US operations. All businesses provide home care services to clients. These operating segments are monitored by the Group's Chief Executive Officer and strategic decisions are made based on segment operating results. Group Head Office provides management oversight and expertise including merger and acquisitions services.

Segment information for the reporting period is as follows:

	For the three months ended September 30, 2025				
	US	Canada	Total Reportable Segments	Group Head Office	Total
	\$	\$	\$	\$	\$
Segment revenues	6,364,472	1,899,854	8,264,326	-	8,264,326
Cost of services	3,734,534	1,257,102	4,991,636	-	4,991,636
Gross margin	2,629,938	642,752	3,272,690	-	3,272,690
Corporate & administrative ⁽ⁱ⁾	1,866,359	423,274	2,289,633	312,351	2,601,984
Amortization and depreciation	163,089	54,189	217,278	16,149	233,427
Stock-based compensation	1,834	909	2,743	15,983	18,726
Segment operating income (loss)	598,656	164,380	763,036	(344,483)	418,553
Segment assets	18,553,130	4,415,840	22,968,970	617,913	23,586,883

Nova Leap Health Corp.

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

(United States dollars)

For the three and nine months ended September 30, 2025 and 2024

11. Segment reporting (continued)

	For the three months ended September 30, 2024				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	5,394,284	1,010,219	6,404,503	2,025	6,406,528
Cost of services	3,248,126	724,520	3,972,646	-	3,972,646
Gross margin	2,146,158	285,699	2,431,857	2,025	2,433,882
Corporate & administrative ⁽ⁱ⁾	1,589,259	184,171	1,773,430	281,336	2,054,766
Amortization and depreciation	117,797	12,050	129,847	16,322	146,169
Stock-based compensation	-	-	-	24,837	24,837
Segment operating income (loss)	439,102	89,478	528,580	(320,470)	208,110
Segment assets	17,561,528	2,864,416	20,425,944	617,173	21,043,117

	For the nine months ended September 30, 2025				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	18,470,606	4,907,989	23,378,595	427	23,379,022
Cost of services	10,925,727	3,190,003	14,115,730	-	14,115,730
Gross margin	7,544,879	1,717,986	9,262,865	427	9,263,292
Corporate & administrative ⁽ⁱ⁾	5,655,536	1,100,892	6,756,428	969,191	7,725,619
Amortization and depreciation	450,711	140,771	591,482	47,588	639,070
Stock-based compensation	5,289	3,056	8,345	46,114	54,459
Segment operating income (loss)	1,433,343	473,267	1,906,610	(1,062,466)	844,144
Segment assets	18,553,130	4,415,840	22,968,970	617,913	23,586,883

	For the nine months ended September 30, 2024				
	US \$	Canada \$	Total Reportable Segments \$	Group Head Office \$	Total \$
Segment revenues	16,257,666	2,910,138	19,167,804	6,977	19,174,781
Cost of services	9,800,835	2,061,388	11,862,223	-	11,862,223
Gross margin	6,456,831	848,750	7,305,581	6,977	7,312,558
Corporate & administrative ⁽ⁱ⁾	4,712,767	562,265	5,275,032	888,712	6,163,744
Amortization and depreciation	350,008	36,241	386,249	49,088	435,337
Stock-based compensation	1,863	3,855	5,718	65,231	70,949
Segment operating income (loss)	1,392,193	246,389	1,638,582	(996,054)	642,528
Segment assets	17,561,528	2,864,416	20,425,944	617,173	21,043,117

ⁱ⁾ Corporate & administrative includes Head office and operations management expenses and general & administrative expenses.

The Group's revenues from external customers and its non-current assets are all attributable to the U.S. and Canada segments. Revenues from external customers are identified based on the client's geographical location. Non-current assets are allocated based on their physical location.